In a historic moment for venture capital diversity, London-based Thena Capital has officially closed its inaugural fund at £45 million ($60.4 million), marking a significant milestone not just for the amount raised, but for who raised it. The firm has become the first venture capital fund in the UK to be led entirely by an all-female general partner team—a breakthrough that underscores both the firm’s commitment to supporting innovation and the ongoing shift toward greater diversity in traditionally male-dominated finance.
What Happened
Thena Capital announced the full close of its debut fund this week, following an initial £27 million close in March 2025. The fund is dedicated to backing early-stage medical technology companies across the United Kingdom, positioning itself at the intersection of healthcare innovation and venture investment. The capital will support founders developing cutting-edge medtech solutions, from diagnostics and therapeutics to digital health platforms and medical devices.
The timing is noteworthy. As the healthcare technology sector continues to mature and attract significant investor attention globally, Thena’s entry brings fresh perspective and capital to the UK medtech ecosystem. The firm’s achievement also arrives amid growing momentum in the venture world to address gender imbalance among decision-makers and fund allocators.
Key Points
The £45 million close represents confidence from limited partners in both Thena’s investment thesis and its team’s ability to identify and nurture promising medtech founders. For US investors tracking the British tech scene, this fund signals that UK medtech remains an attractive investment frontier, with a growing number of specialized vehicles emerging to serve the sector.
Beyond the capital raised, Thena’s all-female GP leadership sends a powerful message to the venture industry about what’s possible when the table includes diverse perspectives. Studies have consistently shown that diverse investment teams often outperform their counterparts, yet women remain dramatically underrepresented in senior VC roles. Thena’s existence challenges that status quo directly.
What This Means
For UK medtech entrepreneurs, particularly female founders who have historically struggled to secure funding, Thena Capital offers both capital and mentorship from leaders who understand the unique challenges they face. Research shows that female-founded companies receive a fraction of VC funding compared to male-led teams, yet often deliver comparable or superior returns.
For the broader venture ecosystem, Thena’s successful close demonstrates that investors are increasingly willing to back GP teams based on merit and track record rather than traditional demographics. As the US venture market continues grappling with diversity and inclusion, the emergence of initiatives like Thena—not as diversity window-dressing but as serious, well-funded investors—offers a template for meaningful change in an industry that has long resisted it.
